clarithromycin has been researched along with Community Acquired Infection in 108 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (15.74) | 18.2507 |
| 2000's | 67 (62.04) | 29.6817 |
| 2010's | 17 (15.74) | 24.3611 |
| 2020's | 7 (6.48) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Chiba, N; Hasegawa, K; Iwata, S; Matsubara, K; Morozumi, M; Nakayama, E; Sunakawa, K; Takayanagi, R; Ubukata, K | 1 |
| Blackman Northwood, J; Coley, MD; Cossins, LR; Creti, R; Del Grosso, M; Farrell, DJ; Pantosti, A | 1 |
| Buzon, RA; Chupak, L; Dougherty, TJ; Falcone, MJ; Farley, KA; Finegan, SM; Flanagan, ME; Girard, D; Granskog, K; Hagen, AE; Hardink, JR; Huband, MD; Kamicker, BJ; Kaneko, T; Knickerbocker, MJ; Li, B; Liras, JL; Magee, TV; Marra, A; Medina, I; Nguyen, TT; Noe, MC; O'Donnell, JP; Obach, RS; Penzien, JB; Reilly, UD; Ripp, SL; Schafer, JR; Shen, Y; Stone, GG; Strelevitz, TJ; Sun, J; Tait-Kamradt, A; Vaz, AD; Whipple, DA; Widlicka, DW; Wishka, DG; Wolkowski, JP | 1 |
| Al-Salloum, J; Gillani, SW; Gulam, SM; Mahmood, RK | 1 |
| Altdorfer, A; Berger, L; Fontaine, C; Herens, S; Mattar, L; Robinet, S; Schils, R | 1 |
| Alharbi, L; Alkhamisi, R; Alradadi, R; Ashy, N; Eljaaly, K | 1 |
| Karpova, OY; Pigusova, NA; Rachina, SA; Sinopalnikov, AI; Vasilyeva, IS | 1 |
| Aljabri, A; Almehmadi, M; Alqahtani, N; Alraddadi, B; Aseeri, MA; Assabban, Z; Bahobail, F; Botaish, A; Eljaaly, K; Hashim, A; Thabit, AK; Torres, A | 1 |
| Adami, ME; Alexiou, N; Giamarellos-Bourboulis, EJ; Gogos, C; Halvatzis, S; Kosmas, V; Koutoukas, P; Kyprianou, A; Kyprianou, M; Kyriakoudi, A; Kyriazopoulou, E; Lada, M; Makina, A; Niederman, MS; Pavlaki, M; Sinapidis, D; Stefos, A; Velissaris, D | 1 |
| Chambers, ST; Doogue, MP; Gardiner, SJ; Metcalf, SC; Werno, A | 1 |
| Akram, A; Chalmers, JD; Hill, AT; Schembri, S; Short, PM; Singanayagam, A; Taylor, J; Williamson, PA | 1 |
| Jin, YH; Li, XM; Wang, FC; Yang, F | 1 |
| Arnold, C; Bassetti, S; Piso, RJ | 1 |
| Cao, B; Chen, R; Du, Y; Hu, B; Hu, Y; Liu, Y; Liu, Z; Su, D; Sun, H; Wang, H; Wang, Z; Xu, X; Zhang, F; Zhang, R; Zhao, C; Zhuo, C | 1 |
| Fujii, T; Ito, A; Nakaminami, H; Noguchi, N; Utsumi, K | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Aolie, J; El-Khatib, WF; Noreddin, AM; Salem, AH; Zhanel, GG | 1 |
| Grobusch, MP; Henning, M; Hira, M; Mithal, Y; Parshotam, K; Rabie, W; Ramdas, Z; Schoeman, HS; Singh, S; Snyman, JR | 1 |
| Asami, R; Chiba, N; Morozumi, M; Murayama, SY; Okada, T; Takahashi, T; Ubukata, K | 1 |
| McKinnell, J; Tayek, JA | 1 |
| Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T | 1 |
| Baranowski, WJ | 1 |
| Barman, TK; Bhadauria, T; Bhateja, P; Bhatnagar, PK; Chakrabarti, A; Das, B; Katoch, R; Kumar, GR; Malhotra, S; Mathur, T; Pandya, M; Rao, M; Rathy, S; Upadhyay, D; Venkataraman, R | 1 |
| Göpfrich, H; Kurz, H | 1 |
| Ashley, EA; Lubell, Y; Turner, P; White, NJ | 1 |
| Mikamo, H; Yamagishi, Y | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Cei, M; Mumoli, N | 1 |
| Eiznhamer, DA; English, ML; Flavin, MT; Fredericks, CE; Jenta, TR; Milanesio, NA; Rohowsky, N; Xu, ZQ | 1 |
| Al-Abri, SS; Al-Maashani, S; Beeching, NJ; Memish, ZA | 1 |
| Bayles, T; Cheng, AC; Choo, S; Tong, E | 1 |
| Duprat-Lomon, I; Lamping, DL; Marquis, P; Marrel, A; Sagnier, PP; Schroter, S | 1 |
| Cabré, X; Falguera, M; Ferrer, G; Pérez, J; Ruiz, A; Sacristán, O; Vallverdú, M | 1 |
| Corris, P; Duprat-Lomon, I; Höffken, G; Kubin, R; Muir, JF; Sagnier, PP; Torres, A | 1 |
| Cravarezza, P; Donati, P; Franchino, L; Grassi, V; Pozzi, A; Prometti, P; Ravizzola, G; Romanelli, G; Zulli, R | 1 |
| Guchev, IA; Klochkov, OI; Ul'ianov, VA | 1 |
| Odagiri, S; Shimada, J; Takahashi, H; Watanuki, Y | 1 |
| Malcolm, C; Marrie, TJ | 1 |
| García, E; González, J; Marco, F; Marcos, MA; Martínez, JA; Mensa, J; Sánchez, F; Soriano, A; Torres, A | 1 |
| Carbon, C; Dunbar, L; Fogarty, C; Hagberg, L; Pullman, J; van Rensburg, DJ | 1 |
| Badaró, R; Bumroongkit, C; Corrêa, JC; Dolmann, AL; Juárez Martínez, LG; Mayrinck, LR; Mera, JR; Tamez, R; Yang, JY | 1 |
| Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Chang, J; Cots, JM; Domínguez-Gil, A; Herreras, A; Rubio-Terrés, C; Sánchez Gascón, F; Trilla, A | 1 |
| Hassman, J; Mathers Dunbar, L; Tellier, G | 1 |
| Aizawa, H; Fujiki, R; Kawayama, T; Rikimaru, T | 1 |
| Demartini, G; Esposti, D; Fraschini, F; Lapidari, A; Marthyn, P; Scaglione, F | 1 |
| Martínez-Vázquez, C; Rodríguez-Suárez, JR; Sabrià, M; Segura, F; Sopena, N; Valencia, A | 1 |
| Aronkyto, T; Chuchalin, AG; Jaaskevi, M; Kahnovskii, I; Kleutgens, K; Lode, H | 1 |
| Asche, CV; Chang, JR; Lavin, B; Stewart, J; Sullivan, SD; Tellier, G | 1 |
| Chang, JR; Niederman, MS; Nieman, RB; Nusrat, R; Stewart, J | 1 |
| Carriere, KC; Jin, Y; Johnson, D; Marrie, T | 1 |
| Asche, CV; Chang, JR; Lavin, B; Niederman, MS; Nusrat, R; Stewart, J; Sullivan, SD | 1 |
| Lavin, B; Niederman, MS; Nusrat, R; Patel, M; Tellier, G | 1 |
| Doherty, GM; Farrell, S; McCallion, WA; Milliken, I; Murphy, JL; Wootton, SA | 1 |
| Iutanova, NS | 1 |
| Beecroft, MD; Herman-Gnjidic, Z; Marrie, TJ | 1 |
| Gotfried, MH | 1 |
| Aurangzeb, B; Hameed, A | 1 |
| Amsden, GW | 1 |
| González-Granda, D; Labrador, T; Martínez, I; Nieto, A; Querol-Borrás, JM; Querol-Ribelles, JM; Tenías, JM | 1 |
| García Vázquez, E; Marcos, MA; Martínez, JA; Mensa, J; Ortega, M; Puig, J; Torres, A | 1 |
| Armstrong, EP; Malone, DC; Ramachandran, S; Skrepnek, GH | 1 |
| Lee, WK; Young, BW | 1 |
| Breen, JD; De Salvo, MC; Drehobl, MA; Lewis, DE | 1 |
| Bishai, WR; Williams, KN | 1 |
| Díaz F, A; Pavié G, J; Prida C, JM; Saldías P, F | 1 |
| Blasi, F; Tarsia, P | 1 |
| Dean, NC; Hadlock, C; Sperry, P; Suchyta, MS; Wikler, M | 1 |
| Barbe, F; García, M; Pifarre Teixido, R; Vicente de Vera, C | 1 |
| Hoban, DJ; Zhanel, GG | 1 |
| Altraja, A; Kullamaa, A; Leesik, H; Meriste, S; Naaber, P; Tamm, E | 1 |
| Blasi, F; de Caprariis, PJ; Feldman, C; Garbino, J; Hoepelman, IM; Hogan, P; Tamm, M; Todisco, T | 1 |
| Abu-Laban, RB; Boudreaux, ED; Camargo, CA; Campbell, SG; Clark, S; Colman, I; Rowe, BH; Sivilotti, ML | 1 |
| Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X | 1 |
| Decramer, M; Martin, M; Moore, L; Quilici, S; Simoens, S | 1 |
| Chen, JM; Huang, LM; Lee, CY; Lee, PI; Wu, MH | 1 |
| Block, S; Cassell, GH; Craft, JC; Hammerschlag, MR; Hedrick, J | 1 |
| Fanti, D; Fraioli, P; Magliano, E; Montanari, G; Montemurro, L; Pozzoli, R; Rizzato, G | 1 |
| Casas, JM; Gómez-Cadiñanos, RA; Oteo, JA; Rosel, L | 1 |
| Chick, TW; Neu, HC | 1 |
| Gard, P; Guion, A; MacFarlane, JT; Prewitt, J | 1 |
| Block, SL; Harris, J; Kolokathis, A; Tarlow, MJ | 1 |
| Huyghens, L; Lauwers, S; Meysman, M; Monsieur, I; Vincken, W | 1 |
| de Torrenté, A; Genné, D; Humair, L; Janin-Jaquat, B; Siegrist, HH | 1 |
| Felmingham, D; Grüneberg, RN; Harding, I; Robbins, MJ; Shrimpton, S; Tesfaslasie, Y | 1 |
| Muller, O; O'Doherty, B | 1 |
| Ramirez, J; Talbot, GH; Townsend, L; Unowsky, J; Zhang, H | 1 |
| Carbon, C; Poole, MD | 1 |
| Carrión Valero, F; Gómez Cubillos, C; Pascual Izuel, JM | 1 |
| Belda, A; Gonzalvo, F; Martínez-Moragón, E; Pascual, JM; Ripollés, F; Rovira, E | 1 |
| Churchyard, GA; Dylewski, JS; Hagberg, L; Moola, S; Sedani, S; Staley, H | 1 |
| Huchon, G | 1 |
| Ali, A; Awad, CE; Dainesi, SM; Matyas, R; Nakatani, J; Rocha, RT; Salazar, MS; Silva, CO; Vital, AC | 1 |
| Dell'Orso, D; Parola, D; Terzano, C | 1 |
| Bayliff, CD; Bombassaro, AM; McCormack, DG; Nolan, T; Offman, E; Varin, F | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| McCarty, JM | 1 |
| Harada, M; Kataoka, M; Kawata, N; Matsuo, K; Nabe, M; Okamoto, M; Tada, S; Takeuchi, M; Yamadori, I | 1 |
| Garanina, TA; Iakovlev, VP; Khlebnikov, EP; Pavlova, MB | 1 |
| Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J | 1 |
| Carabias, ML; Cervera, LA; entelles, ML; García-Navas, BL | 1 |
| Acampora, MD; Busman, TA; Notario, GF; Sokol, WN; Sullivan, JG | 1 |
| Bobbaers, H; Collins, O; Finch, R; Hoeffken, G; Izquierdo, JL; Kubin, R; McGivern, J; Nikolaides, P; Ogundare, F; Raz, R; Schürmann, D; Zuck, P | 1 |
| Busman, TA; Dattani, D; Devcich, KJ; Gotfried, MH; Notario, GF; Palmer, RN; Riffer, E | 1 |
| Aiolfi, S; Beghi, G; Patruno, V | 1 |
15 review(s) available for clarithromycin and Community Acquired Infection
| Article | Year |
|---|---|
Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Community-Acquired Infections; Humans; Pneumonia, Bacterial | 2021 |
Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Erythromycin; Humans; Pneumonia; Randomized Controlled Trials as Topic | 2022 |
Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Erythromycin; Female; Humans; Male; Pneumonia, Bacterial | 2020 |
Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Humans; Ketolides; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 2013 |
Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics.
Topics: Adult; Africa South of the Sahara; Anti-Bacterial Agents; Asia; Azithromycin; Child; Clarithromycin; Community-Acquired Infections; Confounding Factors, Epidemiologic; Drug Resistance, Bacterial; Erythromycin; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Humans; Klebsiella; Macrolides; Microbial Sensitivity Tests; Neisseria meningitidis; Salmonella enterica; Streptococcus agalactiae; Streptococcus pyogenes | 2011 |
[Combination therapy with macrolides for pneumonia].
Topics: Aged; Anti-Bacterial Agents; Bacteria; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Humans; Macrolides; Male; Pneumonia, Bacterial; Practice Guidelines as Topic | 2011 |
Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Ketolides; Macrolides; Naphthyridines; Penicillins; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Humans; Tablets | 2003 |
Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Chronic Disease; Clarithromycin; Community-Acquired Infections; Erythromycin; Humans; Inflammation; Macrolides; Respiratory Tract Infections | 2005 |
Clarithromycin extended-release in community-acquired respiratory tract infections.
Topics: Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Drug Administration Schedule; Humans; Respiratory Tract Infections | 2005 |
Value of short-course antimicrobial therapy in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Microspheres; Ofloxacin; Pneumonia; Time Factors; Treatment Outcome | 2005 |
Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Respiratory Tract Infections; Risk Factors; Streptococcus pneumoniae | 2006 |
Future indications for macrolides.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Helicobacter Infections; Humans; Malaria; Mycobacterium avium-intracellulare Infection; Pneumonia, Bacterial | 1997 |
The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Microbial; Global Health; Humans; Respiratory Tract Infections | 1999 |
Clarithromycin in the management of community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Clarithromycin; Clinical Trials as Topic; Community-Acquired Infections; Humans; Pneumonia, Staphylococcal | 2000 |
46 trial(s) available for clarithromycin and Community Acquired Infection
| Article | Year |
|---|---|
Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drugs, Generic; Female; Humans; Male; Prospective Studies; Respiratory Tract Infections; Single-Blind Method; Therapeutic Equivalency; Treatment Outcome | 2009 |
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Endpoint Determination; Ethnicity; Female; Humans; Ketolides; Male; Middle Aged; Pneumonia; Sex Factors; Treatment Outcome; Young Adult | 2012 |
The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Psychometrics; Quality Assurance, Health Care; Quinolines; Surveys and Questionnaires | 2002 |
[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Female; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, Bacterial; Treatment Outcome | 2002 |
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumonia; Quinolines | 2003 |
Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Community-Acquired Infections; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Hospitalization; Humans; Imipenem; Male; Meropenem; Pneumonia, Bacterial; Prospective Studies; Thienamycins; Treatment Outcome | 2002 |
[Evaluation of clarithromycin efficacy in the treatment of community-acquired pneumonia on the basis of the Binax NOW test results (a prospective open trial)].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antigens, Bacterial; Chromatography; Clarithromycin; Community-Acquired Infections; Gastrointestinal Diseases; Humans; Immunologic Techniques; Male; Military Personnel; Pneumonia, Pneumococcal; Prospective Studies; Reagent Kits, Diagnostic; Sputum; Streptococcus pneumoniae; Urticaria | 2002 |
Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Follow-Up Studies; Humans; Length of Stay; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2003 |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral st
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Erythromycin; Female; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia | 2003 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Resistance, Bacterial; Female; Humans; Ketolides; Macrolides; Male; Middle Aged; Pneumonia | 2004 |
[Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Interferon-gamma; Interleukin-10; Interleukin-6; Male; Middle Aged; Penicillins; Pneumonia | 2004 |
Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pneumonia; Prospective Studies | 2004 |
A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Hospitalization; Humans; Ketolides; Macrolides; Male; Middle Aged; Pneumonia; Treatment Outcome | 2004 |
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Hospitalization; Humans; Ketolides; Macrolides; Male; Middle Aged; Pneumonia; Treatment Outcome | 2004 |
Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Hospitalization; Humans; Ketolides; Macrolides; Male; Middle Aged; Pneumonia, Bacterial | 2004 |
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Resistance, Bacterial; Electrocardiography; Enzyme Induction; Female; Haemophilus influenzae; Humans; Ketolides; Liver Function Tests; Macrolides; Male; Middle Aged; Moraxella catarrhalis; Pneumonia; Sample Size; Sputum; Streptococcus pneumoniae; Treatment Outcome | 2004 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Family Health; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Recurrence; Urea | 2004 |
[Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2004 |
Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2004 |
Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefuroxime; Child, Preschool; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Female; Humans; Infant; Length of Stay; Male; Pneumonia; Time Factors | 2003 |
Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2005 |
Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Microspheres; Middle Aged; Pneumonia | 2005 |
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Length of Stay; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 2006 |
Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia; Prospective Studies; Random Allocation; Treatment Outcome | 2007 |
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Ofloxacin; Pneumonia; Treatment Outcome | 2007 |
An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chlamydia Infections; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Erythromycin; Female; Humans; Infant; Infant, Newborn; Male; Mycoplasma Infections; Pneumonia; Treatment Outcome | 2008 |
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
Topics: Child; Child, Preschool; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Erythromycin Ethylsuccinate; Female; Humans; Male; Pneumonia, Mycoplasma; Prospective Studies; Treatment Outcome | 1995 |
Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.
Topics: Adult; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1995 |
Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
Topics: Adult; Aged; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Bacteria; Cefixime; Cefotaxime; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Respiratory Tract Infections; United States | 1993 |
Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Penicillins; Respiratory Tract Infections; Single-Blind Method | 1996 |
Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 1997 |
Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pneumonia, Bacterial; Quinolones | 1999 |
Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime.
Topics: Adult; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial | 1999 |
A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 1999 |
Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis; Chronic Disease; Clarithromycin; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia; Spiramycin | 1999 |
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Fluoroquinolones; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Moxifloxacin; Nasopharynx; Pneumonia, Bacterial; Quinolines | 2000 |
[Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis; Bronchopneumonia; Clarithromycin; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pharyngitis; Respiratory Tract Infections; Tonsillitis | 2000 |
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Confidence Intervals; Double-Blind Method; Female; Fluoroquinolones; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Recurrence; Treatment Outcome | 2001 |
A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Naphthyridines; Pneumonia; Prospective Studies; Radiography; Treatment Outcome | 2002 |
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Treatment Outcome | 2002 |
[Clarithromycin switch therapy in adult patients suffering from community-acquired lower respiratory tract infections (LRTIs) requiring hospitalisation].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Female; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Respiratory Tract Infections | 2001 |
47 other study(ies) available for clarithromycin and Community Acquired Infection
| Article | Year |
|---|---|
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; RNA, Ribosomal, 23S | 2008 |
Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial; Global Health; Humans; Macrolides; Membrane Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Population Surveillance; Respiratory Tract Infections; Sequence Analysis, DNA; Streptococcal Infections; Streptococcus pyogenes | 2009 |
Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.
Topics: Animals; Azetidines; Bacteria; Community-Acquired Infections; Disease Susceptibility; Drug Discovery; Drug Resistance, Multiple; Drug-Related Side Effects and Adverse Reactions; Humans; Ketolides; Mice; Microbial Sensitivity Tests; Respiratory Tract Infections | 2009 |
[Clarithromycin consumption at the University Hospital of Liege in 2019. Retrospective study].
Topics: Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Hospitals; Humans; Macrolides; Retrospective Studies | 2022 |
[Clarithromycin for community-acquired pneumonia in adults: focus on anti-inflammatory properties].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; C-Reactive Protein; Clarithromycin; Community-Acquired Infections; Female; Humans; Interleukin-6; Male; Middle Aged; Pneumonia; Tumor Necrosis Factor-alpha; Young Adult | 2023 |
Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Cohort Studies; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2020 |
A persuasive approach to antimicrobial stewardship in Christchurch hospitals produced a sustained decrease in intravenous clarithromycin dosing and expenditure via a switch to azithromycin orally.
Topics: Administration, Intravenous; Administration, Oral; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Clarithromycin; Community-Acquired Infections; Dosage Forms; Guideline Adherence; Hospitals; Humans; New Zealand; Pneumonia | 2020 |
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Disease Progression; Female; Follow-Up Studies; Guideline Adherence; Hospitalization; Humans; Male; Middle Aged; Pneumonia; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Risk Factors; United Kingdom | 2013 |
Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; beta-Lactams; Chlamydial Pneumonia; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Guideline Adherence; Hospitalization; Humans; Immunocompromised Host; Legionnaires' Disease; Macrolides; Male; Middle Aged; Odds Ratio; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Pneumonia, Pneumococcal; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Severity of Illness Index | 2013 |
[Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillins; Respiratory Tract Infections; Streptococcus pneumoniae | 2015 |
Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital.
Topics: Bacterial Toxins; Bacterial Typing Techniques; Cefotaxime; Chromosomes, Bacterial; Clarithromycin; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterotoxins; Exotoxins; Humans; Interspersed Repetitive Sequences; Japan; Leukocidins; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Staphylococcal Infections; Superantigens; Tertiary Care Centers; Virulence Factors | 2015 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Ketolides; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia, Pneumococcal; Probability; Streptococcus pneumoniae | 2009 |
Prolonged Mycoplasma pneumoniae infection in an elderly patient with community-acquired pneumonia.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Female; Frail Elderly; Humans; Minocycline; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Sputum | 2009 |
Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.
Topics: Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Colchicine; Community-Acquired Infections; Doxycycline; Drug Interactions; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pneumonia, Bacterial; Rhabdomyolysis; Treatment Outcome | 2009 |
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Female; Humans; Kaplan-Meier Estimate; Legionella pneumophila; Legionnaires' Disease; Length of Stay; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Clarithromycin-induced hypomania in a child - a case report.
Topics: Administration, Oral; Anti-Bacterial Agents; Bipolar Disorder; Child, Preschool; Clarithromycin; Community-Acquired Infections; Humans; Male; Pneumonia, Bacterial | 2010 |
Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Drug Evaluation, Preclinical; Haemophilus influenzae; Humans; Mice; Microbial Sensitivity Tests; Moraxella catarrhalis; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Time Factors | 2010 |
[Epidemiology and morbidity of mycoplasma as causative agent for community-acquired pneumonia in hospitalized children in a Community Hospital in Vienna].
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Austria; C-Reactive Protein; Cefuroxime; Child; Clarithromycin; Community-Acquired Infections; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hospitalization; Hospitals, Community; Humans; Incidence; Infusions, Intravenous; Length of Stay; Macrolides; Male; Pneumonia, Mycoplasma; Prospective Studies | 2011 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Clinical images: community-acquired pneumonia.
Topics: Adult; Anti-Bacterial Agents; Chest Pain; Clarithromycin; Community-Acquired Infections; Cough; Humans; Leukocyte Count; Lung; Male; Penicillins; Pneumonia, Bacterial; Radiography; Severity of Illness Index | 2012 |
An audit of inpatient management of community-acquired pneumonia in Oman: a comparison with regional clinical guidelines.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Disease Management; Female; Guideline Adherence; Hospitalization; Humans; Male; Medical Audit; Middle Aged; Oman; Pneumonia; Practice Guidelines as Topic; Quality of Health Care; Retrospective Studies; Severity of Illness Index | 2012 |
Clarithromycin for community-acquired pneumonia: beware drug interactions.
Topics: Aged; Clarithromycin; Community-Acquired Infections; Drug Interactions; Humans; Pneumonia; Retrospective Studies | 2012 |
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Chronic Disease; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Lactams; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors | 2001 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2003 |
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluoroquinolones; France; Germany; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2003 |
[Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin].
Topics: Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Costs and Cost Analysis; Decision Trees; Economics, Pharmaceutical; Humans; Ketolides; Macrolides; Pneumonia; Randomized Controlled Trials as Topic; Retrospective Studies | 2003 |
Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Prescriptions; Drug Utilization; Female; Hospital Mortality; Hospitalization; Humans; Male; Odds Ratio; Pneumonia; Preventive Health Services; Retrospective Studies; Sulfamethoxazole; Survival Rate; Trimethoprim | 2004 |
Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cefotaxime; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Humans; Pneumonia, Bacterial | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Databases as Topic; Erythromycin; Female; Health Care Costs; Humans; Levofloxacin; Male; Managed Care Programs; Middle Aged; Models, Econometric; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Treatment Outcome | 2005 |
Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Clavulanic Acid; Community-Acquired Infections; Drug Prescriptions; Erythromycin; Hong Kong; Humans; Infant; Penicillin Resistance; Pneumonia, Pneumococcal; Practice Guidelines as Topic; Prevalence; Streptococcus pneumoniae | 2005 |
[Assessment of the management of community-acquired pneumonia in adults outpatients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Emergencies; Female; Frail Elderly; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Prospective Studies; Treatment Failure | 2005 |
Delirium induced by clarithromycin in a patient with community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delirium; Female; Humans; Middle Aged; Pneumonia, Bacterial | 2006 |
Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cefuroxime; Child; Child, Preschool; Ciprofloxacin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Estonia; Female; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Respiratory Tract Infections; Streptococcus pneumoniae | 2006 |
Community-acquired pneumonia in North American emergency departments: drug resistance and treatment success with clarithromycin.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Emergency Service, Hospital; Female; Humans; Male; Middle Aged; North America; Pneumonia; Prospective Studies; Sputum; Streptococcus pneumoniae | 2007 |
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; Cefuroxime; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
Clarithromycin-induced thrombocytopenic purpura.
Topics: Aged; Clarithromycin; Community-Acquired Infections; Humans; Male; Pneumonia, Bacterial; Purpura, Thrombocytopenic | 1994 |
Severe community-acquired pneumonia caused by atypical organisms.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Clarithromycin; Clavulanic Acids; Community-Acquired Infections; Critical Care; Diagnosis, Differential; Drug Therapy, Combination; Erythromycin; Female; Gentamicins; Humans; Male; Middle Aged; Netilmicin; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Psittacosis; Radiography; Treatment Failure | 1997 |
Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactam Resistance; beta-Lactamases; Cefaclor; Cephalosporins; Ciprofloxacin; Clarithromycin; Common Cold; Community-Acquired Infections; Dose-Response Relationship, Drug; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Multicenter Studies as Topic; Penicillins; Respiratory System; Respiratory Tract Infections; Streptococcus pneumoniae; United Kingdom | 1998 |
[Can macrolide treatment delay the diagnosis of tuberculosis?].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Female; Humans; Pneumonia; Time Factors; Tuberculosis, Pulmonary | 1999 |
How to manage the low-risk patient with lower respiratory tract infection?
Topics: Ambulatory Care; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Humans; Pneumonia; Risk Factors | 1999 |
[Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Clarithromycin; Community-Acquired Infections; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia; Risk Factors; Smoking; Time Factors | 2000 |
Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia.
Topics: Absorption; Acute Disease; Administration, Oral; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Convalescence; Female; Humans; Male; Mouth Mucosa; Pneumonia, Bacterial; Prognosis; Prospective Studies; Radiography; Severity of Illness Index | 2000 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |
[Pulmonary Nocardia otitidiscaviarum infection in an immunocompetent host].
Topics: Aged; Amikacin; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Humans; Immunocompromised Host; Male; Nocardia; Nocardia Infections; Pneumonia; Treatment Outcome | 2000 |
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Community-Acquired Infections; Drug Resistance; Fluoroquinolones; Humans; Meningococcal Infections; Microbial Sensitivity Tests; Naphthyridines; Nasopharynx; Neisseria meningitidis; Respiratory Tract Infections; Rifampin; Time Factors | 2001 |